Related Experiment Video
Updated: Jun 4, 2026

Sexual Crosses with the Mucoromycete Phycomyces blakesleeanus
Published on: June 6, 2025
Mucormycosis of the head and neck
1E. Wolfson Hospital, Holon, 58100, Israel, midan@post.tau.ac.il.
Abstract:
Mucormycosis of the head and neck is the most common form of infection by the order Mucorales, accounting for up to half of all cases. About 70% of rhinocerebral cases develop in diabetic patients. Less often, rhinocerebral mucormycosis occurs in solid organ transplant recipients, those with prolonged neutropenia, and those on deferoxamine therapy. Recently, rhinocerebral disease has been increasingly recognized in patients undergoing hematopoietic stem cell transplantation. A growing number of cases have presented as breakthrough infection in patients receiving voriconazole. The mortality rate of rhinocerebral mucormycosis has remained at 30% to 70% despite aggressive therapy. Early initiation of treatment substantially improves outcome, underscoring the need to maintain a high index of suspicion and promptly biopsy potential lesions. Surgical excision of necrotic tissue is essential. Lipid formulations of amphotericin B have become the standard treatment for mucormycosis. Posaconazole is useful as salvage therapy, but cannot be recommended yet as primary therapy.
Insights
Head and neck mucormycosis, a serious fungal infection, often affects diabetic patients and transplant recipients. Early diagnosis and aggressive treatment, including surgery and amphotericin B, are crucial for improving outcomes in this high-mortality condition.
Area of Science:
- Mycology
- Infectious Diseases
- Otolaryngology
Background:
- Head and neck mucormycosis, caused by Mucorales fungi, represents up to 50% of all mucormycosis cases.
- Rhinocerebral mucormycosis predominantly affects diabetic patients (approx. 70%) and is also observed in transplant recipients, those with neutropenia, or on deferoxamine therapy.
- Emerging risk factors include hematopoietic stem cell transplantation and breakthrough infections in patients receiving voriconazole.
Purpose of the Study:
- To review the epidemiology, risk factors, and current management strategies for head and neck mucormycosis.
- To emphasize the critical need for early diagnosis and prompt intervention to improve patient survival rates.
- To discuss the role of surgical debridement and antifungal therapies in treating this invasive fungal infection.
Main Methods:
- Literature review of rhinocerebral mucormycosis cases and treatment outcomes.
- Analysis of patient populations at risk, including immunocompromised individuals and those with specific medical conditions.
- Evaluation of current therapeutic guidelines and emerging treatment options.
Main Results:
- Rhinocerebral mucormycosis has a high mortality rate, ranging from 30% to 70%, despite aggressive treatment.
- Early treatment initiation is strongly associated with improved patient outcomes.
- Surgical excision of necrotic tissue is a cornerstone of effective management.
Conclusions:
- Head and neck mucormycosis requires a high index of suspicion for prompt diagnosis, often necessitating biopsy of suspicious lesions.
- Lipid formulations of amphotericin B are the current standard of care for mucormycosis treatment.
- Posaconazole may be considered for salvage therapy, but its role as primary treatment is not yet established.
Related Concept Videos
Cryptococcal Meningitis
Fungal Group Zygomycota
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Candidiasis
Veins of Head and Neck
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
Fungal Phylum Ascomycota
